Table 3.

Summary of poliovirus type 1 vaccine virus detected among participants by select study arms.

Vaccine virus shedding	Arm A		Arm B		Arm C		Arm D		Fisher’s Exact Test
	mOPV1 + fIPV6		mOPV1 + fIPV10		mOPV1		bOPV
	(n = 301)		(n = 295)		(n = 298)		(n = 298)
Baseline*, 6 weeks	–	–	4/294	1% (0–4%)	6/297	2% (1–5%)	6/296	2% (1–5%)
One week, 7 weeks	–	–	253/290	87% (83–91%)	240/291	83% (78–87%)	233/290	80% (75–85%)	B/C v D: p = 0.10
Two weeks, 8 weeks	–	–	234/290	81% (76–85%)	209/291	72% (66–77%)	162/290	56% (50–62%)	B/C v D: p < 0.0001
Baseline*, 14 weeks	41/295	14% (10–19%)	39/288	14% (10–18%)	50/294	17% (13–22%)	–	–
One week, 15 weeks	51/254	20% (15–26%)	24/249	10% (6–14%)	52/244	21% (17–27%)			A vs C: p = 0.74 B vs C: p = 0.0004
Two weeks, 16 weeks	25/254	10% (6–14%)	14/249	6% (3–10%)	35/244	14% (10–20%)			A v C: p = 0.13 B vs C: p = 0.0014

Data are the percentage of participants with vaccine virus detected in stool specimens expressed as n/N and percentage including 95% confidence interval (CI).

^*Restricted to participants who were not shedding at baseline (either 6 weeks or 14 weeks depending on objective) and had stool specimen results available one week and two weeks post-vaccination. mOPV1 = monovalent oral poliovirus vaccine type 1, fIPV = fractional inactivated poliovirus vaccine, bOPV = bivalent oral poliovirus vaccine. Fisher’s Exact test was used to test for inequality of proportions between study arms.